Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susumu Imoto

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 14, 2004
[Autoimmune hepatitis and HCV]Toshiki Komeda, Yoshihiro Fukuda, Susumu Imoto
Alcoholism, Clinical and Experimental Research|August 20, 2004
Hypervascular liver nodules in heavy drinkers of alcoholSoo Ryang Kim, Yoko Maekawa, Susumu Imoto, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|December 24, 2016
Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis CSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 24, 2015
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovirSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapyAhmed El-Shamy, Motoko Nagano-Fujii, Noriko Sasase, et al.
Microbiology and Immunology|April 21, 2007
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment seraAhmed El-Shamy, Mikiko Sasayama, Motoko Nagano-Fujii, et al.
Intervirology|February 5, 2011
Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapyAhmed El-Shamy, Soo-Ryang Kim, Yoshi-Hiro Ide, et al.
Digestive Diseases (Basel, Switzerland)|October 22, 2015
Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging DetectabilityKayo Sugimoto, Soo Ryang Kim, Susumu Imoto, et al.
Pathology International|July 16, 2016
Confluent hepatic fibrosis in alcohol liver cirrhosis with elevated pivkaii value - usefulness of immunostaining for EZH2 and p16(INK4a) in differentiating it from cholangiolocellular carcinoma - Confluent hepatic fibrosisSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
World Journal of Gastroenterology|September 1, 2010
Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cmKeiji Mita, Soo Ryang Kim, Masatoshi Kudo, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 14, 2004
[Autoimmune hepatitis and HCV]Toshiki Komeda, Yoshihiro Fukuda, Susumu Imoto
Alcoholism, Clinical and Experimental Research|August 20, 2004
Hypervascular liver nodules in heavy drinkers of alcoholSoo Ryang Kim, Yoko Maekawa, Susumu Imoto, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|December 24, 2016
Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis CSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 24, 2015
Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovirSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapyAhmed El-Shamy, Motoko Nagano-Fujii, Noriko Sasase, et al.
Microbiology and Immunology|April 21, 2007
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment seraAhmed El-Shamy, Mikiko Sasayama, Motoko Nagano-Fujii, et al.
Intervirology|February 5, 2011
Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapyAhmed El-Shamy, Soo-Ryang Kim, Yoshi-Hiro Ide, et al.
Digestive Diseases (Basel, Switzerland)|October 22, 2015
Characteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging DetectabilityKayo Sugimoto, Soo Ryang Kim, Susumu Imoto, et al.
Pathology International|July 16, 2016
Confluent hepatic fibrosis in alcohol liver cirrhosis with elevated pivkaii value - usefulness of immunostaining for EZH2 and p16(INK4a) in differentiating it from cholangiolocellular carcinoma - Confluent hepatic fibrosisSoo Ki Kim, Soo Ryang Kim, Susumu Imoto, et al.
World Journal of Gastroenterology|September 1, 2010
Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cmKeiji Mita, Soo Ryang Kim, Masatoshi Kudo, et al.
Pageof 6